ALDH3A1 and head and neck squamous cell carcinoma: In head and neck squamous cell carcinoma, activation of ALDH3A1 increases chemoresistance against cisplatin whereas combining cisplatin with an ALDH inhibitor results in more pronounced cell viability reduction than treatment with each compound alone [30].